Complete testing solution optimizes time and money spent on programs to
save more lives
HALIFAX, March 18, 2014 /CNW/ - MedMira Inc. (TSXV: MIR) will submit a new application for its most advanced Reveal Rapid HIV
Antibody Test (Reveal HIV) to the WHO Prequalification of Diagnostics
Programme. The latest version of Reveal HIV, recently approved in the
European Union, delivers faster and more convenient point-of-care
testing in the field through its simplified test procedure and the
direct use of whole blood specimens. These new features are also in
the Reveal and Multiplo products currently being commercialized in
preparation for FDA submission.
The MedMira management team made the decision to submit its most
advanced Reveal HIV test to the WHO for prequalification based on the
company's commitment to offer state-of-the-art technology and testing
solutions to every corner of the world. Prequalification of the latest
Reveal HIV format will also enable MedMira's global strategic partners
to bring the best technology and products to all markets where care
providers and patients can benefit from faster, more cost-effective
testing solutions. As MedMira rolls out this advanced version of Reveal
HIV around the globe, legacy products will be phased out and the
company will no longer support previous versions of the test, including
the format originally submitted to the WHO for prequalification.
"Healthcare providers around the world are demanding the most advanced
technology that qualified rapid test developers have to offer in order
to meet the increasing need for screening tools that help prevent and
control the spread of deadly diseases like HIV. By submitting Reveal
HIV, built on the latest advances in our Rapid Vertical Flow
Technology, for prequalification, MedMira is answering the WHO's call
for state-of-the art, innovative products needed in their programs,"
said Hermes Chan, CEO, MedMira Inc.
Chan added, "Cost efficiency combined with high quality tests are
critical to all government and non-government organizations running
testing programs. MedMira is creating new modelling tools to help care
providers optimize their program outputs and maximize available
budgets, especially important in regions where large scale screening
programs have the most impact. Our goal is to provide a comprehensive
testing solution that includes the most advanced diagnostic technology,
the highest quality tests, and optimization tools to save lives."
About MedMira
MedMira is a leading developer and manufacturer of vertical flow rapid
diagnostics. The Company's tests provide hospitals, labs, clinics and
individuals with instant diagnosis for diseases such as HIV and
hepatitis C in just three easy steps. The Company's tests are sold
under the Reveal®, Multiplo™ and Miriad™ brands in global markets.
Based on its patented Rapid Vertical Flow Technology™, MedMira's rapid
HIV test is the only one in the world to achieve regulatory approvals
in Canada, the United States, China and the European Union. MedMira's
corporate offices and manufacturing facilities are located in Halifax,
Nova Scotia, Canada. For more information visit medmira.com.
This news release contains forward-looking statements, which involve
risk and uncertainties and reflect the Company's current expectation
regarding future events including statements regarding possible
approval and launch of new products, future growth, and new business
opportunities. Actual events could materially differ from those
projected herein and depend on a number of factors including, but not
limited to, changing market conditions, successful and timely
completion of clinical studies, uncertainties related to the regulatory
approval process, establishment of corporate alliances and other risks
detailed from time to time in the company quarterly filings.
Neither TSX Venture Exchange nor its Regulation Services Provider (as
that term is defined in the policies of the TSX Venture Exchange)
accepts responsibility for the adequacy or accuracy of this release.
SOURCE MedMira Inc.
